202 related articles for article (PubMed ID: 33531652)
41. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
42.
Satapathy S; Mittal BR; Sood A; Das CK; Mavuduru RS; Goyal S; Shukla J; Singh SK
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1754-1764. PubMed ID: 34842950
[TBL] [Abstract][Full Text] [Related]
43. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
[TBL] [Abstract][Full Text] [Related]
44. [Metastatic prostate cancer : Update: position paper for the use of chemotherapy].
Ohlmann CH; Goebell PJ; Grimm MO; Klier J; König F; Machtens S; Schostak M; Schrader AJ; Albers P
Urologe A; 2017 Dec; 56(12):1597-1602. PubMed ID: 28695241
[TBL] [Abstract][Full Text] [Related]
45. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE;
Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602
[TBL] [Abstract][Full Text] [Related]
46. Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
Passildas-Jahanmohan J; Eymard JC; Pouget M; Kwiatkowski F; Van Praagh I; Savareux L; Atger M; Durando X; Abrial C; Richard D; Ginzac Couvé A; Thivat E; Monange B; Chollet P; Mahammedi H
Cancer Med; 2021 Apr; 10(7):2332-2340. PubMed ID: 33666378
[TBL] [Abstract][Full Text] [Related]
47. Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study.
Hung SC; Chang LW; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Chen CC; Wang SC; Lin CY; Cheng CL; Ou YC; Chiu KY
In Vivo; 2021; 35(6):3509-3519. PubMed ID: 34697189
[TBL] [Abstract][Full Text] [Related]
48. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Halabi S; Yang Q; Roy A; Luo B; Araujo JC; Logothetis C; Sternberg CN; Armstrong AJ; Carducci MA; Chi KN; de Bono JS; Petrylak DP; Fizazi K; Higano CS; Morris MJ; Rathkopf DE; Saad F; Ryan CJ; Small EJ; Kelly WK
J Clin Oncol; 2023 May; 41(15):2736-2746. PubMed ID: 37040594
[TBL] [Abstract][Full Text] [Related]
49. Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.
Wilkerson J; Abdallah K; Hugh-Jones C; Curt G; Rothenberg M; Simantov R; Murphy M; Morrell J; Beetsch J; Sargent DJ; Scher HI; Lebowitz P; Simon R; Stein WD; Bates SE; Fojo T
Lancet Oncol; 2017 Jan; 18(1):143-154. PubMed ID: 27979599
[TBL] [Abstract][Full Text] [Related]
50. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
51. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
Chi KN; Higano CS; Blumenstein B; Ferrero JM; Reeves J; Feyerabend S; Gravis G; Merseburger AS; Stenzl A; Bergman AM; Mukherjee SD; Zalewski P; Saad F; Jacobs C; Gleave M; de Bono JS
Lancet Oncol; 2017 Apr; 18(4):473-485. PubMed ID: 28283282
[TBL] [Abstract][Full Text] [Related]
52. Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study.
Byeon S; Kim H; Kim J; Kwon M; Hur JY; Jeon HG; Jeon SS; Lee HM; Park SH
Investig Clin Urol; 2020 Nov; 61(6):588-593. PubMed ID: 32985144
[TBL] [Abstract][Full Text] [Related]
53. Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.
Crombag MBS; de Vries Schultink AHM; van Doremalen JGC; Otten HM; Bergman AM; Schellens JHM; Beijnen JH; Huitema ADR
Drugs Aging; 2019 Apr; 36(4):379-385. PubMed ID: 30734241
[TBL] [Abstract][Full Text] [Related]
54. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
55. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
56. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
Carles J; Pichler A; Korunkova H; Tomova A; Ghosn M; El Karak F; Makdessi J; Koroleva I; Barnes G; Bury D; Özatilgan A; Hitier S; Katolicka J
BJU Int; 2019 Mar; 123(3):456-464. PubMed ID: 30098093
[TBL] [Abstract][Full Text] [Related]
57. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
[TBL] [Abstract][Full Text] [Related]
58. Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network.
Bianchi S; Mosca A; Dalla Volta A; Prati V; Ortega C; Buttigliero C; Fea E; Vanella P; Valcamonico F; Zamparini M; Sirotova Z; Chiappino I; Dal Canton O; Masini C; Sacco C; Amoroso D; Montagnani F; Comandone A; Bellissimo AR; Ciccone G; Baier S; Gennari A; Tucci M; Berruti A
Eur J Cancer; 2021 Sep; 155():127-135. PubMed ID: 34371442
[TBL] [Abstract][Full Text] [Related]
59. Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
Tanaka N; Nishimura K; Okajima E; Ina K; Ogawa O; Nagata H; Akakura K; Fujimoto K; Gotoh M; Teramukai S; Hirao Y
Int J Urol; 2019 Aug; 26(8):797-803. PubMed ID: 31055879
[TBL] [Abstract][Full Text] [Related]
60. Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
Madan RA; Karzai FH; Al Harthy M; Petrylak DP; Kim JW; Arlen PM; Rosner I; Theoret MR; Cordes L; Bilusic M; Peer CJ; Dawson NA; Couvillon A; Hankin A; Williams M; Chun G; Owens H; Marte JL; Lee MJ; Tomita Y; Yuno A; Trepel JB; Lee S; Steinberg SM; Gulley JL; Figg WD; Dahut WL
BJU Int; 2021 Apr; 127(4):435-444. PubMed ID: 32969563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
